Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-02

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)

View source ↗

Summary

FDA approved a supplemental application for Buprenorphine and Naloxone (buprenorphine/naloxone) from Sun Pharmaceutical Industries, Inc. under an ANDA. This act…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)